ClinicalTrials.gg
CompletedNCT00420199Updated Jan 18, 2012Results posted

A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

A Phase 3 interventional study of Abatacept and Placebo in Active Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 10 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-18.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
42nd of 63
50 · median 119
Started
2007
with 5 others
Phase 3
26 of 63
2 open now
Registered
15th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 42nd largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 15th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The only trial in participants who are methotrexate-inadequate responders and have active Rheumatoid Arthritis, in which gadolinium-enhanced Magnetic Resonance Imaging; Bone Mineral Density; and biochemical markers of bone, cartilage, and synovial tissue metabolism are used to evaluate early effects (4 months) of Abatacept on inflammation/structural damage. Study will provide valuable mechanism-of-action information on how Abatacept exerts its effects (including on bone) through new techniques.

03

Conditions studied

  • Active Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Disease activity as defined by a Disease Activity Score 28-C-Reactive Protein (CRP) >3.2 or >6 swollen and ≥6 tender joints and CRP greater than the
  • At least 1 erosion in hands/wrists or positive anticyclic citrullinated peptides or rheumatoid factor
  • Clinically detectable synovitis of at least 1 wrist/ankle at screening and baseline
  • Participants must have been treated with methotrexate, on a weekly dose of at least 15 mg or a maximum tolerated dose (such as, 10 mg weekly) for at least 3 months before screening. Dose of methotrexate must be stable for at least 28 days prior to the first study dose (Day 1)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Abatacept + Methotrexate (Double-blind period)

    Drug: Abatacept

  • Placebo comparator
    Placebo + Methotrexate (Double-blind period)

    Drug: Placebo

Interventions

  • Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment

    Also known as: (BMS-188667), Orencia

  • DrugPlacebo

    Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment

06

What researchers measure

Primary outcomes

  1. Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)

    Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.

    Time frame: At baseline

  2. Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA

    Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis=Follow-up synovitis score-baseline score.

    Time frame: Baseline to Day 113

  3. Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis

    Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis score=Follow-up synovitis score-baseline synovitis score.

    Time frame: Baseline to Day 113

Secondary outcomes

  1. Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores

    Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.

    Time frame: At baseline

  2. Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores

    Bone erosion assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached hand. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. Total erosion score for hands/wrists is sum of the individual scores for each location. Thus the maximum score per hand/wrist is 230. Increasing score=greater severity. Adjusted change from baseline in erosion score=mean score at Day 113-mean erosion score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.

    Time frame: Baseline to Day 113

  3. Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores

    Osteitis assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) \* 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity.

    Time frame: At baseline

  4. Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores

    Osteitis assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached. Each site scored in 1.0 increments, indicating involvement of original articular bone (0=none to 3=severe). Total score for hands/wrists is sum of scores for each location. Maximum score per hand/wrist is 23 (total anatomic locations)\*3 (maximum score per joint)=69. Minimum score=0(normal). Increasing score=greater severity. Adjusted mean change from baseline in osteitis score=mean score at Day 113-mean score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.

    Time frame: Baseline to Day 113

  5. Double-blind Period: Number of Participants With Newly Involved Joints in Bone Erosion, Edema/Osteitis, and Synovitis

    Bone erosion and osteitis were assessed at a total of 23 anatomic locations according to erosion (for bone erosion) or involvement (for osteitis) of the original articular bone. Synovitis assessed as above-normal post-gadolinium enhancement in 3 wrist regions: distal radioulnar joint, radiocarpal joint, and intercarpal and carpometacarpal joints.

    Time frame: Baseline to Day 113

  6. Double-blind Period: Baseline Mean RAMRIS Scores

    RAMRIS score is the sum of its core components: Synovitis Score, Osteitis Score, and Erosion Score. Synovitis scored from 0 (normal) to 9 (maximum distension of synovial cavity). Osteitis scored 0 (normal) to 69 (maximum articular bone involvement). Erosion scored from 0 (normal) to 230 (maximum erosion of articular bone). RAMRIS=Synovial Score + Osteitis Score + Erosion Score. Minimum RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Osteitis Score, Erosion Score, and RAMRIS score, increasing number=increasing severity.

    Time frame: Baseline

  7. Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores

    RAMRIS Score=sum of core components: Synovitis (S), Osteitis (O), and Erosion (E) Scores. S scored 0 (none) to 9 (maximum distension of synovial cavity); O scored 0 (none) to 69 (maximum articular bone involvement); E scored 0 (none) to 230 (maximum erosion of articular bone). RAMRIS=S+O+E Scores. RAMRIS minimum score=0 (normal), maximum=308 (severe structural damage). Adjusted change from baseline in RAMRIS=mean RAMRIS at Day 113-mean RAMRIS at baseline. Adjustment based on ANCOVA model: treatment=factor, baseline value=covariate.

    Time frame: Baseline to Day 113

  8. Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Formation: Osteocalcin and Serum Intact N-terminal Propeptide of Type I Procollagen (PINP)

    PINP and osteocalcin are markers of bone formation. Osteocalcin is synthesized by osteoblasts and is associated with osteoblast synthetic activity. Osteoblasts secrete type 1 procollagen, and cleavage of large fragments from the carboxy and amino terminal ends result in formation of mature type 1 collagen and production of PINP fragments.

    Time frame: Baseline to Days 15, 29, 57, 85, and 113

  9. Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Destruction (Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen [CTX-I] and Serum Pyridinoline Cross-linked Telopeptide Domain of Type I Collagen [ICTP])

    CTX-I and ICTP are biochemical markers of bone resorption or bone degradation

    Time frame: Baseline to Days 15, 29, 57, 85, and 113

  10. Double-blind Period: Median Percent Change From Baseline in a Systemic Marker of Cartilage Degradation (Creatinine-corrected Urinary Carboxyterminal Crosslinking Telopeptide of Type II Collagen [UCTX2C])

    Urinary CTX-II is a biochemical marker of type II collagen breakdown. In participants with early rheumatoid arthritis, increased levels of CTX-II can be predictive of rapid radiographic progression over periods of 1 to 5 years. These markers of cartilage destruction can predict progression of joint damage, independent of clinical and biologic indices of disease activity and baseline joint damage.

    Time frame: Baseline to Days 15, 29, 57, 85, and 113

  11. Double-blind Period: Median Percent Change From Baseline in Systemic Marker of Synovial Tissue Metabolism (Creatinine-corrected Urinary Glucosyl-Galactosyl-Pyridinoline [UGGPC])

    Glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) is a specific biochemical marker reflecting the degradation of the synovial tissue membrane. It is a glycosylated derivative of the collagen crosslink pyridinoline, and it is present in significant amounts only in the synovial membrane; it is absent from bone and present in minutes amounts in cartilage and other soft tissues. Increased urinary levels of Glc-Gal-PYD have been found in early and long-standing rheumatoid arthritis, high levels being associated with rapid destruction.

    Time frame: Baseline to Days 15, 29, 57, 85, and 113

  12. Double-blind Period: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  13. Double-blind Period: Number of Participants With AEs of Special Interest

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including serious, opportunistic, and all other infections; autoimmune disorders; neoplasms; acute infusional AEs (prespecified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (prespecified AEs occurring within 24 hours of start of infusion).

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  14. Double-blind Period: Number of Participants With Infections/Infestations of Special Interest

    Infections/Infestations of Special Interest are AEs and SAEs considered possibly, probably, or certainly related to study treatment, graded according to Common Terminology Criteria for Adverse Events Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death). AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment.

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  15. Double-blind Period: Number of Participants With Acute Infusional AEs of Special Interest

    Acute infusional AEs are AEs with onset during the first hour after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events ,Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  16. Double-blind Period: Number of Participants With Peri-infusional AEs of Special Interest

    Peri-infusional AEs are AEs occurring during the first 24 hours after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events, Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  17. Double-blind Period: Number of Participants With Laboratory Test Results in Hematology Meeting the Criteria for Marked Abnormality

    BL=baseline; LLN=lower limit of normal; ULN=upper limit of normal. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL. Hematocrit: \<0.75\*BL. Erythrocytes: \<0.75\*BL. Platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL \<LLN, use 0.5\*BL/\<100,000 mm\^3. Leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use \<0.8\*BL/\>ULN, or if BL\>ULN, use \>1.2\*BL/\<LLN. Neutrophils+bands: \<1.0\*10\^3 c/uL. Eosinophils: \>0.750\*10\^3 c/uL. Basophils: \> 400 mm\^3. Monocytes: \>2000 mm\^3. Lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  18. Double-blind Period: Number of Participants With Laboratory Test Results for Liver and Kidney Function Meeting Criteria for Marked Abnormality

    ULN=upper limit of normal; BL=baseline. Marked abnormality criteria: Alkaline phosphatase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase: \>3\*ULN, or if BL\>ULN,use \>4\*BL; alanine aminotransferase: \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-Glutamyl transferase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; Bilirubin: \>2\*ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\*BL; creatinine: \>1.5\*BL.

    Time frame: From Day 1 to Day 113, and including up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  19. Double-blind Period: Number of Participants With Laboratory Test Results for Electrolytes Meeting the Criteria for Marked Abnormality

    LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Marked abnormality: Sodium: \<0.95\*LLN/\>1.05\*ULN,or if BL\<LLN, use 0.95\*BL or \>ULN,or if BL\>ULN, use\>1.05\*BL or \<LLN. Potassium: \<0.9\*LLN/\>1.1\* ULN,or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Chloride: \<0.9\*LLN/\>1.1\*ULN, or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Calcium: \<0.8\*LLN/\>1.2\*ULN, or if BL\<LLN, use 0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\*BL or \<LLN. Phosphorous: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\*BL or \<LLN.

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  20. Double-blind Period: Number of Participants With Laboratory Test Results in Other Chemistries and Urinalysis Meeting the Criteria for Marked Abnormality

    LLN=lower limit of normal; ULN=upper limit of normal; BL-baseline. Marked abnormality c: serum glucose:\<65 mg/dL/\>220 mg/dL; fasting serum glucose: \<0.8\* LLN/\>1.5\* ULN, or if BL\<LLN, use 0.8\*BL or \>ULN, or if BL\>ULN, use \>2.0\*BL or \<LLN; total protein: \<0.9\*LLN/\>1.1\* ULN; albumin: \<0.9\*LLN,or if BL\<LLN, use \<0.75 BL; uric acid: \>1.5\* ULN, or if BL\>ULN, use \>2\*BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, red blood cells, white blood cells):Use ≥2 when BL value missing or value ≥4,or when predose=0 or 0.5. Use ≥3 when predose=1. Use ≥4 when predose=2 or 3

    Time frame: From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period

  21. Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs

    Vital signs, which included blood pressure, heart rate, respiration, and temperature, were monitored predose and 1 hour after start of infusion. Changes in vital signs were determined to be significantly abnormal at the discretion of the investigator but were generally those that either exceeded, or failed to reach, normal parameters. Normal vital sign parameter ranges varied by site.

    Time frame: Days 1, 15, 29, 57, 85, and 113

  22. Double-blind Period: Number of Participants With Positive Antibodies to Abatacept by Electrochemiluminescence (ECL) Assay

    On-Rx=on treatment; post-Rx=post treatment. ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1.

    Time frame: Day 1 to Day 113

07

Results

Posted May 17, 2011

Participant flow

Participant flow — Overall Study
MilestoneAbatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTX
Started2723
Completed2623
Not completed10
Withdrew: Participant no longer met study criteria10

Outcome measures

PrimaryDouble-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)

Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.

Time frame:
At baseline
Reported as:
Mean · units on a scale
Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)4.48 ± 2.103.52 ± 2.43
SecondaryDouble-blind Period: Baseline Mean Erosion OMERACT 6 Scores

Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.

Time frame:
At baseline
Reported as:
Mean · units on a scale
Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores12.60 ± 9.419.65 ± 10.11
SecondaryDouble-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores

Bone erosion assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached hand. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. Total erosion score for hands/wrists is sum of the individual scores for each location. Thus the maximum score per hand/wrist is 230. Increasing score=greater severity. Adjusted change from baseline in erosion score=mean score at Day 113-mean erosion score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.

Time frame:
Baseline to Day 113
Reported as:
Mean · units on a scale
Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores0.45 ± 0.430.95 ± 0.45
Statistical analysis
  • Abatacept + Methotrexate vs Placebo + Methotrexate · ANCOVA · Adjusted mean difference from placebo: -0.50 · 95% CI -1.77 to 0.76
PrimaryDouble-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA

Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis=Follow-up synovitis score-baseline score.

Time frame:
Baseline to Day 113
Reported as:
Mean · units on a scale
Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA-0.44 ± 1.470.52 ± 1.38
Statistical analysis
  • Abatacept + Methotrexate vs Placebo + Methotrexate · ANCOVA · p = 0.103 · Mean difference (final values): 0.96
SecondaryDouble-blind Period: Baseline Mean Osteitis OMERACT 6 Scores

Osteitis assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) \* 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity.

Time frame:
At baseline
Reported as:
Mean · units on a scale
Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores7.72 ± 7.048.00 ± 9.72
SecondaryDouble-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores

Osteitis assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached. Each site scored in 1.0 increments, indicating involvement of original articular bone (0=none to 3=severe). Total score for hands/wrists is sum of scores for each location. Maximum score per hand/wrist is 23 (total anatomic locations)\*3 (maximum score per joint)=69. Minimum score=0(normal). Increasing score=greater severity. Adjusted mean change from baseline in osteitis score=mean score at Day 113-mean score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.

Time frame:
Baseline to Day 113
Reported as:
Mean · units on a scale
Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores-1.94 ± 0.861.54 ± 0.90
Statistical analysis
  • Abatacept + Methotrexate vs Placebo + Methotrexate · ANCOVA · Adjusted mean difference from placebo: -3.48 · 95% CI -6.00 to -0.96
SecondaryDouble-blind Period: Number of Participants With Newly Involved Joints in Bone Erosion, Edema/Osteitis, and Synovitis

Bone erosion and osteitis were assessed at a total of 23 anatomic locations according to erosion (for bone erosion) or involvement (for osteitis) of the original articular bone. Synovitis assessed as above-normal post-gadolinium enhancement in 3 wrist regions: distal radioulnar joint, radiocarpal joint, and intercarpal and carpometacarpal joints.

Time frame:
Baseline to Day 113
Reported as:
Number · participants
Double-blind Period: Number of Participants With Newly Involved Joints in Bone Erosion, Edema/Osteitis, and Synovitis
participantsAbatacept + MethotrexatePlacebo + Methotrexate
0 newly involved joints (Bone Erosion)2016
≥1 newly involved joints (Bone Erosion)57
0 newly involved joints (Edema/Osteitis)1816
≥1 newly involved joints (Edema/Osteitis)77
0 newly involved joints (Synovitis)2320
≥1 newly involved joints (Synovitis)23
SecondaryDouble-blind Period: Baseline Mean RAMRIS Scores

RAMRIS score is the sum of its core components: Synovitis Score, Osteitis Score, and Erosion Score. Synovitis scored from 0 (normal) to 9 (maximum distension of synovial cavity). Osteitis scored 0 (normal) to 69 (maximum articular bone involvement). Erosion scored from 0 (normal) to 230 (maximum erosion of articular bone). RAMRIS=Synovial Score + Osteitis Score + Erosion Score. Minimum RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Osteitis Score, Erosion Score, and RAMRIS score, increasing number=increasing severity.

Time frame:
Baseline
Reported as:
Mean · units on a scale
Double-blind Period: Baseline Mean RAMRIS Scores
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Baseline Mean RAMRIS Scores24.80 ± 16.3621.17 ± 20.45
SecondaryDouble-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores

RAMRIS Score=sum of core components: Synovitis (S), Osteitis (O), and Erosion (E) Scores. S scored 0 (none) to 9 (maximum distension of synovial cavity); O scored 0 (none) to 69 (maximum articular bone involvement); E scored 0 (none) to 230 (maximum erosion of articular bone). RAMRIS=S+O+E Scores. RAMRIS minimum score=0 (normal), maximum=308 (severe structural damage). Adjusted change from baseline in RAMRIS=mean RAMRIS at Day 113-mean RAMRIS at baseline. Adjustment based on ANCOVA model: treatment=factor, baseline value=covariate.

Time frame:
Baseline to Day 113
Reported as:
Mean · units on a scale
Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores
units on a scaleAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores-1.82 ± 1.132.89 ± 1.18
Statistical analysis
  • Abatacept + Methotrexate vs Placebo + Methotrexate · ANCOVA · Adjusted mean difference from placebo: -4.71 · 95% CI -8.00 to -1.42
SecondaryDouble-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Formation: Osteocalcin and Serum Intact N-terminal Propeptide of Type I Procollagen (PINP)

PINP and osteocalcin are markers of bone formation. Osteocalcin is synthesized by osteoblasts and is associated with osteoblast synthetic activity. Osteoblasts secrete type 1 procollagen, and cleavage of large fragments from the carboxy and amino terminal ends result in formation of mature type 1 collagen and production of PINP fragments.

Time frame:
Baseline to Days 15, 29, 57, 85, and 113
Reported as:
Median · percent change
Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Formation: Osteocalcin and Serum Intact N-terminal Propeptide of Type I Procollagen (PINP)
percent changeAbatacept + MethotrexatePlacebo + Methotrexate
Day 15 osteocalcin (n=25, n=21)1.82 (-10.2 to 12.1)4.41 (-12.7 to 15.6)
Day 15 serum intact PINP (n=25, n=21)6.83 (-3.9 to 15.7)3.94 (-8.4 to 13.9)
Day 29 osteocalcin (n=26, n=21)2.43 (-8.8 to 18.2)12.14 (-10.1 to 19.2)
Day 29 serum intact PINP (n=26, n=21)11.62 (1.1 to 30.8)-0.18 (-9.3 to 23.5)
Day 57 osteocalcin (n=25, n=21)4.02 (-7.7 to 25.4)10.53 (-3.7 to 22.8)
Day 57 serum intact PINP (n=25, n=21)3.68 (-8.1 to 43.1)12.18 (-6.7 to 20.2)
Day 85 osteocalcin (n=24, n=21)4.76 (-11.5 to 34.1)10.62 (-14.8 to 25.8)
Day 85 serum intact PINP (n=24, n=21)5.97 (-10.6 to 36.3)-7.23 (-18.1 to 14.8)
Day 113 osteocalcin (n=24, n=21)3.18 (-8.2 to 11.8)7.87 (-8.3 to 19.0)
Day 113 serum intact PINP (n=24, n=21)2.98 (-19.8 to 28.8)4.75 (-16.1 to 24.7)
SecondaryDouble-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Destruction (Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen [CTX-I] and Serum Pyridinoline Cross-linked Telopeptide Domain of Type I Collagen [ICTP])

CTX-I and ICTP are biochemical markers of bone resorption or bone degradation

Time frame:
Baseline to Days 15, 29, 57, 85, and 113
Reported as:
Median · percent change
Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Destruction (Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen [CTX-I] and Serum Pyridinoline Cross-linked Telopeptide Domain of Type I Collagen [ICTP])
percent changeAbatacept + MethotrexatePlacebo + Methotrexate
Day 15 CTX-1 (n=25, n=21)1.65 (-23.0 to 13.0)-6.37 (-24.6 to 23.2)
Day 15 ICTP (n=25, n=21)-5.56 (-17.1 to 10.9)6.25 (-6.2 to 18.6)
Day 29 CTX-1 (n=26, n=21)0.48 (-28.2 to 32.2)-0.72 (-21.2 to 18.6)
Day 29 ICTP (n=26, n=21)-3.47 (-10.1 to 10.0)4.34 (-3.7 to 20.4)
Day 57 CTX-1 (n=25, n=21)15.13 (-17.9 to 26.5)7.02 (-11.4 to 16.7)
Day 57 ICTP (n=25, n=21)-5.08 (-15.9 to 14.5)8.73 (-3.7 to 21.6)
Day 85 CTX-1 (n=24, n=21)-6.94 (-35.9 to 21.5)15.65 (-18.9 to 40.8)
Day 85 ICTP (n=24, n=21)-6.36 (-24.7 to 4.7)2.25 (-7.1 to 9.7)
Day 113 CTX-1 (n=24, n=21)-7.23 (-36.4 to 21.3)0.00 (-27.5 to 35.3)
Day 113 ICTP (n=24, n=21)-11.29 (-27.7 to 1.5)11.64 (-2.2 to 29.9)
SecondaryDouble-blind Period: Median Percent Change From Baseline in a Systemic Marker of Cartilage Degradation (Creatinine-corrected Urinary Carboxyterminal Crosslinking Telopeptide of Type II Collagen [UCTX2C])

Urinary CTX-II is a biochemical marker of type II collagen breakdown. In participants with early rheumatoid arthritis, increased levels of CTX-II can be predictive of rapid radiographic progression over periods of 1 to 5 years. These markers of cartilage destruction can predict progression of joint damage, independent of clinical and biologic indices of disease activity and baseline joint damage.

Time frame:
Baseline to Days 15, 29, 57, 85, and 113
Reported as:
Median · percent change
Double-blind Period: Median Percent Change From Baseline in a Systemic Marker of Cartilage Degradation (Creatinine-corrected Urinary Carboxyterminal Crosslinking Telopeptide of Type II Collagen [UCTX2C])
percent changeAbatacept + MethotrexatePlacebo + Methotrexate
Day 15 UCTX2C (n=24, n=21)-8.51 (-35.9 to 13.7)5.14 (-11.7 to 8.4)
Day 29 UCTX2C (n=21, n=19)-3.40 (-16.5 to 5.8)6.81 (-25.1 to 13.5)
Day 57 UCTX2C (n=23, n=19)0.24 (-50.0 to 25.0)5.43 (-12.3 to 24.8)
Day 85 UCTX2C (n=22, n=20)-10.83 (-38.4 to 14.7)9.67 (-13.8 to 29.2)
Day 113 UCTX2C (n=22, n=20)-18.49 (-46.9 to 54.2)9.86 (-22.4 to 46.3)
SecondaryDouble-blind Period: Median Percent Change From Baseline in Systemic Marker of Synovial Tissue Metabolism (Creatinine-corrected Urinary Glucosyl-Galactosyl-Pyridinoline [UGGPC])

Glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) is a specific biochemical marker reflecting the degradation of the synovial tissue membrane. It is a glycosylated derivative of the collagen crosslink pyridinoline, and it is present in significant amounts only in the synovial membrane; it is absent from bone and present in minutes amounts in cartilage and other soft tissues. Increased urinary levels of Glc-Gal-PYD have been found in early and long-standing rheumatoid arthritis, high levels being associated with rapid destruction.

Time frame:
Baseline to Days 15, 29, 57, 85, and 113
Reported as:
Median · percent change
Double-blind Period: Median Percent Change From Baseline in Systemic Marker of Synovial Tissue Metabolism (Creatinine-corrected Urinary Glucosyl-Galactosyl-Pyridinoline [UGGPC])
percent changeAbatacept + MethotrexatePlacebo + Methotrexate
Day 15 UGGPC (n=24, n=20)4.44 (-20.5 to 65.0)-3.84 (-13.7 to 12.4)
Day 29 UGGPC (n=22, n=18)-1.83 (-19.3 to 76.9)-3.19 (-25.6 to 26.8)
Day 57 UGGPC (n=23, n=16)1.58 (-24.8 to 23.4)5.73 (-12.6 to 28.2)
Day 85 UGGPC (n=22, n=18)0.32 (-31.0 to 54.5)16.29 (-14.4 to 39.7)
Day 113 UGGPC (n=22, n=18)-12.16 (-27.9 to 53.3)-3.10 (-31.5 to 32.3)
SecondaryDouble-blind Period: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Deaths00
SAEs02
Treatment-related SAEs00
SAEs Leading to Discontinuation00
AEs2014
Treatment-related AEs86
AEs Leading to Discontinuation00
SecondaryDouble-blind Period: Number of Participants With AEs of Special Interest

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including serious, opportunistic, and all other infections; autoimmune disorders; neoplasms; acute infusional AEs (prespecified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (prespecified AEs occurring within 24 hours of start of infusion).

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With AEs of Special Interest
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Infections10
Malignancies00
Autoimmune disorders00
Acute infusional AEs04
Peri-infusional AEs45
SecondaryDouble-blind Period: Number of Participants With Infections/Infestations of Special Interest

Infections/Infestations of Special Interest are AEs and SAEs considered possibly, probably, or certainly related to study treatment, graded according to Common Terminology Criteria for Adverse Events Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death). AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment.

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Infections/Infestations of Special Interest
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period: Number of Participants With Infections/Infestations of Special Interest10
SecondaryDouble-blind Period: Number of Participants With Acute Infusional AEs of Special Interest

Acute infusional AEs are AEs with onset during the first hour after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events ,Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Acute Infusional AEs of Special Interest
participantsAbatacept + MethotrexatePlacebo (PLA) + MTX
Grade 1 diarrhea01
Grade 1 overdose01
Grade 1 headache01
Grade 1 flushing01
SecondaryDouble-blind Period: Number of Participants With Peri-infusional AEs of Special Interest

Peri-infusional AEs are AEs occurring during the first 24 hours after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events, Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Peri-infusional AEs of Special Interest
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Grade 1 nausea30
Grade 1 headache01
Grade 2 headache11
Grade 1 flushing02
Grade 2 arthralgia01
Grade 1 cough01
SecondaryDouble-blind Period: Number of Participants With Laboratory Test Results in Hematology Meeting the Criteria for Marked Abnormality

BL=baseline; LLN=lower limit of normal; ULN=upper limit of normal. Marked abnormality criteria: Hemoglobin: \>3 g/dL decrease from BL. Hematocrit: \<0.75\*BL. Erythrocytes: \<0.75\*BL. Platelets: \<0.67\*LLN/\>1.5\*ULN, or if BL \<LLN, use 0.5\*BL/\<100,000 mm\^3. Leukocytes: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use \<0.8\*BL/\>ULN, or if BL\>ULN, use \>1.2\*BL/\<LLN. Neutrophils+bands: \<1.0\*10\^3 c/uL. Eosinophils: \>0.750\*10\^3 c/uL. Basophils: \> 400 mm\^3. Monocytes: \>2000 mm\^3. Lymphocytes: \<0.750\*10\^3 c/uL/\>7.50\*10\^3 c/uL.

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Laboratory Test Results in Hematology Meeting the Criteria for Marked Abnormality
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Low hemoglobin01
Low hematocrit01
Low erythrocytes00
Low platelets00
High platelets01
Low leukocytes00
High leukocytes10
Low neutrophils+bands01
Low lymphocytes22
High lymphocytes00
High monocytes00
High basophils00
High eosinophils00
SecondaryDouble-blind Period: Number of Participants With Laboratory Test Results for Liver and Kidney Function Meeting Criteria for Marked Abnormality

ULN=upper limit of normal; BL=baseline. Marked abnormality criteria: Alkaline phosphatase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; aspartate aminotransferase: \>3\*ULN, or if BL\>ULN,use \>4\*BL; alanine aminotransferase: \>3\*ULN, or if BL\>ULN, use \>4\*BL; G-Glutamyl transferase: \>2\*ULN, or if BL\>ULN, use \>3\*BL; Bilirubin: \>2\*ULN, or if BL\>ULN, use \>4\*BL; blood urea nitrogen: \>2\*BL; creatinine: \>1.5\*BL.

Time frame:
From Day 1 to Day 113, and including up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Laboratory Test Results for Liver and Kidney Function Meeting Criteria for Marked Abnormality
participantsAbatacept + MethotrexatePlacebo + Methotrexate
High alkaline phosphatase00
High aspartate aminotransferase00
High alanine aminotransferase00
High G-Glutamyl transferase00
High bilirubin00
High blood urea nitrogen00
High creatinine10
SecondaryDouble-blind Period: Number of Participants With Laboratory Test Results for Electrolytes Meeting the Criteria for Marked Abnormality

LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Marked abnormality: Sodium: \<0.95\*LLN/\>1.05\*ULN,or if BL\<LLN, use 0.95\*BL or \>ULN,or if BL\>ULN, use\>1.05\*BL or \<LLN. Potassium: \<0.9\*LLN/\>1.1\* ULN,or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Chloride: \<0.9\*LLN/\>1.1\*ULN, or if BL\<LLN, use 0.9\*BL or \>ULN, or if BL\>ULN, use\>1.1\*BL or \<LLN. Calcium: \<0.8\*LLN/\>1.2\*ULN, or if BL\<LLN, use 0.75\*BL or \>ULN, or if BL\>ULN, use\>1.25\*BL or \<LLN. Phosphorous: \<0.75\*LLN/\>1.25\*ULN, or if BL\<LLN, use 0.67\*BL or \>ULN, or if BL\>ULN, use\>1.33\*BL or \<LLN.

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Laboratory Test Results for Electrolytes Meeting the Criteria for Marked Abnormality
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Low sodium00
High sodium00
Low potassium00
High potassium10
Low chloride00
High chloride00
Low calcium00
High calcium00
Low phosphorous00
High phosphorous00
SecondaryDouble-blind Period: Number of Participants With Laboratory Test Results in Other Chemistries and Urinalysis Meeting the Criteria for Marked Abnormality

LLN=lower limit of normal; ULN=upper limit of normal; BL-baseline. Marked abnormality c: serum glucose:\<65 mg/dL/\>220 mg/dL; fasting serum glucose: \<0.8\* LLN/\>1.5\* ULN, or if BL\<LLN, use 0.8\*BL or \>ULN, or if BL\>ULN, use \>2.0\*BL or \<LLN; total protein: \<0.9\*LLN/\>1.1\* ULN; albumin: \<0.9\*LLN,or if BL\<LLN, use \<0.75 BL; uric acid: \>1.5\* ULN, or if BL\>ULN, use \>2\*BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, red blood cells, white blood cells):Use ≥2 when BL value missing or value ≥4,or when predose=0 or 0.5. Use ≥3 when predose=1. Use ≥4 when predose=2 or 3

Time frame:
From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period
Reported as:
Number · participants
Double-blind Period: Number of Participants With Laboratory Test Results in Other Chemistries and Urinalysis Meeting the Criteria for Marked Abnormality
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Low serum glucose (n=27, n=23)10
High serum glucose (n=27, n=23)11
Low fasting glucose (n=20, n=17)00
High fasting glucose (n=20, n=17)10
Low total protein (n=27, n=23)00
High total protein (n=27, n=23)00
Low albumin (n=27, n=23)00
High uric acid (n=27, n=23)00
High urine protein (n=27, n=23)11
High urine glucose (n=27, n=23)00
High urine blood (n=27, n=23)21
High leukocyte esterase (n=27, n=23)44
High urine white blood cells (n=10, n=9)23
High urine red blood cells (n=10, n=8)33
PrimaryDouble-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis

Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\*3 wrist regions), indicating most severe damage. Change in synovitis score=Follow-up synovitis score-baseline synovitis score.

Time frame:
Baseline to Day 113
Reported as:
Mean · units on a scale
Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis
units on a scaleAbatacept + MethotrexatePlacebo (PLA) + MTX
Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis-0.31 ± 0.260.38 ± 0.27
Statistical analysis
  • Abatacept + Methotrexate vs Placebo (PLA) + MTX · ANCOVA · p = 0.078 · Mean difference (net): 0.69
SecondaryDouble-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs

Vital signs, which included blood pressure, heart rate, respiration, and temperature, were monitored predose and 1 hour after start of infusion. Changes in vital signs were determined to be significantly abnormal at the discretion of the investigator but were generally those that either exceeded, or failed to reach, normal parameters. Normal vital sign parameter ranges varied by site.

Time frame:
Days 1, 15, 29, 57, 85, and 113
Reported as:
Number · participants
Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs
participantsAbatacept + MethotrexatePlacebo + Methotrexate
Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs00
SecondaryDouble-blind Period: Number of Participants With Positive Antibodies to Abatacept by Electrochemiluminescence (ECL) Assay

On-Rx=on treatment; post-Rx=post treatment. ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1.

Time frame:
Day 1 to Day 113
Reported as:
Number · participants
Double-blind Period: Number of Participants With Positive Antibodies to Abatacept by Electrochemiluminescence (ECL) Assay
participantsAbatacept + Methotrexate
Overall on-Rx visits, CTLA4 + possibly Ig (n=27)0
Overall on-Rx visits, Ig and/or junction (n=27)0
Overall post-Rx visits, CTLA4 + possibly Ig (n=1)0
Overall post-Rx visits, Ig and/or junction (n=1)0
Overall visits, CTLA4 + possibly Ig (n=27)0
Overall visits, Ig and/or junction (n=27)0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABA + MTX—0/27 (0%)12/27 (44.4%)
PLA + MTX—2/23 (8.7%)8/23 (34.8%)
Most frequent serious events
Most frequent serious events
EventABA + MTXPLA + MTX
ATRIAL FIBRILLATIONCardiac disorders0/271/23
OVERDOSEInjury, poisoning and procedural complications0/271/23
Most frequent other events
Showing 10 of 11
Most frequent other events
EventABA + MTXPLA + MTX
NAUSEAGastrointestinal disorders4/270/23
BACK PAINMusculoskeletal and connective tissue disorders3/270/23
FLUSHINGVascular disorders0/272/23
HEADACHENervous system disorders1/272/23
NASOPHARYNGITISInfections and infestations1/272/23
EPISTAXISRespiratory, thoracic and mediastinal disorders0/272/23
DIZZINESSNervous system disorders2/270/23
DIARRHOEAGastrointestinal disorders2/271/23
SINUSITISInfections and infestations2/270/23
COUGHRespiratory, thoracic and mediastinal disorders2/271/23

Baseline characteristics

Age Continuous
Age Continuous(years)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Mean51.7 ± 11.252.5 ± 11.552.1 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Female161632
Male11718
Region of Enrollment
Region of Enrollment(participants)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Belgium9716
Germany10616
Netherlands347
Spain224
Sweden235
United Kingdom112
Rheumatoid Factor (RF) Status
Rheumatoid Factor (RF) Status(participants)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Negative12416
Positive151934
Anti-CCP2 Status
Anti-CCP2 Status(participants)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Negative14620
Positive131730
Duration of Rheumatoid Arthritis
Duration of Rheumatoid Arthritis(months)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Mean25.7 ± 18.028.2 ± 17.026.8 ± 17.4
Disease Activity Score (DAS) 28 (C-Reactive Protein [CRP])
Disease Activity Score (DAS) 28 (C-Reactive Protein [CRP])(units on a scale)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Mean5.3 ± 1.15.3 ± 0.95.3 ± 1.0
Number of Tender Joints
Number of Tender Joints(joints)Abatacept (ABA) + Methotrexate (MTX)Placebo (PLA) + MTXTotal
Mean12.9 ± 7.113.3 ± 7.213.1 ± 7.2

2 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Yvoir, 5530, Belgium
  • Local Institution
    Berlin, 14059, Germany
  • Local Institution
    Berlin, BE-10117, Germany
  • Local Institution
    Amsterdam, 1105 AZ, Netherlands
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Barcelona, 08907, Spain
  • Local Institution
    Stockholm, 171 76, Sweden
  • Local Institution
    London, Greater London SE19RT, United Kingdom
  • Local Institution
    Leeds, North Yorkshire LS7 4SA, United Kingdom
09

References and documents

Publications

  • Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, Catrina AI, DiCarlo J, Gaillez C, Le Bars M, Zhou X, Peterfy C. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013 Aug;72(8):1287-94. doi: 10.1136/annrheumdis-2012-201611. Epub 2012 Aug 21. PubMed 22915624 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Aug 2009 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2007
First posted
Jan 9, 2007
Start
May 2007
Primary completionActual
Aug 2009
CompletionActual
May 2010
Results first posted
May 17, 2011
Last update
Jan 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00420199
Responsible party
Sponsor
First posted
Jan 9, 2007
Start date
May 2007
Primary completion
Aug 2009
Completion
May 2010
Results posted
May 17, 2011
Last update
Jan 18, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion